BackAerovate Therapeutics Overview

Aerovate Therapeutics Long Term Debt

Aerovate Therapeutics's long-term debt is $680K.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$679000.00

Peer average

Loading

Aerovate Therapeutics Long Term Debt History

Loading

Aerovate Therapeutics vs. peers: Long Term Debt Comparison

Loading

Aerovate Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Aerovate Therapeutics (AVTE) FAQ

Aerovate Therapeutics (AVTE) currently reports a long-term debt of $680K as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Aerovate Therapeutics's long-term debt history and peer comparisons.

Aerovate Therapeutics's long-term debt changed from $0 to $680K (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aerovate Therapeutics reported $680K in long-term debt as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $680K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Aerovate Therapeutics, and consider following AVTE for alerts when major investors trade the stock.

Aerovate Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $680K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AVTE with unrelated industries.